Production (Stage)
Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -201.15% | -77.99% | -98.65% | -- | -96.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -201.15% | -77.99% | -98.65% | -- | -96.48% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -201.15% | -77.99% | -98.65% | -- | -96.48% |
| SG&A Expenses | 11.40% | -30.05% | -19.02% | -24.90% | -23.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.47% | -12.00% | 46.32% | 22.54% | -5.07% |
| Operating Income | 1.50% | -4.44% | -79.29% | -22.54% | -8.62% |
| Income Before Tax | 121.95% | -255.07% | 21.87% | -1.30% | 58.62% |
| Income Tax Expenses | 192.42% | -257.78% | -97.12% | -- | 29.41% |
| Earnings from Continuing Operations | 119.41% | -234.46% | 25.13% | -0.49% | 58.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.41% | -234.46% | 25.13% | -0.49% | 58.39% |
| EBIT | 1.50% | -4.44% | -79.29% | -22.54% | -8.62% |
| EBITDA | 1.49% | -4.42% | -79.53% | -22.58% | -8.55% |
| EPS Basic | 119.40% | -244.44% | 25.00% | -1.05% | 58.64% |
| Normalized Basic EPS | 121.43% | -233.33% | 22.22% | -1.69% | 56.25% |
| EPS Diluted | 119.40% | -244.44% | 25.00% | -1.05% | 58.64% |
| Normalized Diluted EPS | 121.43% | -233.33% | 22.22% | -1.69% | 56.25% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.11% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |